Stockscreener 앱 받기
207.94
2.10%
-4.46
Abbvie Inc 주식(ABBV)의 최신 뉴스
AbbVie (ABBV) to Present Promising Trial Results at SGO Annual M - GuruFocus
AbbVie stock falls 2.05% as new ovarian cancer data shared at SGO meeting - Traders Union
AbbVie Showcases Late?Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx in Platinum?Sensitive Ovarian Cancer at SGO 2026 - Investing News Network
Significant BD revenue contribution: Hisun Q1 net profit forecast increases up to nearly 11 times. Another major BD deal worth $745 million signed with AbbVie. - 富途牛牛
AbbVie ovarian cancer drug shows 62.7% response rate in trial - Investing.com
Haisco Pharmaceutical Signs Licensing Agreement With AbbVie Group - TradingView — Track All Markets
AbbVie's ELAHERE Demonstrates Unexpected PSOC Effectiveness, Boosting Anticipated Expansion - Bitget
AbbVie stock price forecast: sellers in control as ABBV fails to hold above support - Traders Union
Massachusetts Financial Firm Trims Stake in AbbVie - National Today
-2.05% for AbbVie stock as renewed selling keeps shares below key resistance - Traders Union
Factory Mutual Insurance Co. Decreases AbbVie Stock Position - National Today
AbbVie (ABBV) Receives a Buy from RBC Capital - The Globe and Mail
CapEx per share of AbbVie, Inc. – BSESOF:4AB - TradingView — Track All Markets
AbbVie Inc. stock underperforms Friday when compared to competitors - MarketWatch
Sector Update: Health Care - Moomoo
3 Companies Aggressively Raising Dividends While Others Play Defense - Investing.com
MML Fundamental Value Fund's AbbVie Inc(ABBV) Holding History - GuruFocus
RBC Capital reiterates Abbvie stock Outperform rating at $260 target - Investing.com
Battle of Big Pharma: Is AbbVie Stock Pulling Ahead of Pfizer? - Yahoo Finance
Night Vision Disturbances Pipeline 2026: MOA, ROA, - openPR.com
AbbVie First-Quarter Earnings Unlikely to Lift Sentiment, RBC Says - Moomoo
Guggenheim Adjusts Price Target on AbbVie to $249 From $242, Maintains Buy Rating - marketscreener.com
Dividend Roundup: AGNC Investments, Abbott Labs, AbbVie, and more (AGNC:NASDAQ) - Seeking Alpha
Guggenheim raises Abbvie stock price target to $249 on immunology By Investing.com - Investing.com Canada
Daner Wealth Management, LLC's AbbVie Inc(ABBV) Holding History - GuruFocus
BNY Mellon Worldwide Growth Fund, Inc.'s AbbVie Inc(ABBV) Holding History - GuruFocus
AbbVie Sues Over 340B Patient Definition In Chicago Area - Hoodline
AbbVie: Fairly Valued And Positioned For Growth (NYSE:ABBV) - Seeking Alpha
Cantor Fitzgerald Lowers AbbVie (ABBV) Target, Sees Weak Pharma Catalyst Ahead - Yahoo Finance
ABBV Stock Quote Price and Forecast - CNN
Is AbbVie (ABBV) Still Attractive After Recent Pullback And Mixed Valuation Signals - simplywall.st
TrumpRx adds more drugs as AbbVie, Genentech join self-pay platform - TechTarget
AbbVie: Buy Or Sell Ahead Of Q1 Earnings? It's A Buy, But With Caveats (Upgrade) (ABBV) - Seeking Alpha
AbbVie wades into drug discount fight, suing feds over provider audits - Crain's Chicago Business
AbbVie challenges 340B patient definition in US court - The Pharma Letter
Exclusive: AbbVie sues to narrow drug discount patient definition - Axios
Lobbying Update: $80,000 of ABBVIE INC. lobbying was just disclosed - Quiver Quantitative
AbbVie Dividend Growth & Portfolio Outlook 2026News and Statistics - IndexBox
AbbVie Says 340B Program Defines 'Patient' Too Broadly - Law360
AbbVie files lawsuit to address 'outdated' drug discount eligibility program - Reuters
AbbVie Sue US Over ‘Patient’ Definition Under Drug Discount Plan - Bloomberg Law News
Buying pressure lifts AbbVie stock higher in today's trading - Traders Union
AbbVie sues to narrow 340B eligibility - FirstWord Pharma
AbbVie (ABBV) Challenges Government's Drug Discount Program Defi - GuruFocus
AbbVie : moves to close loopholes and strengthen accountability in 340B program - marketscreener.com
Abbvie Files Lawsuit To Address 340B Program Guidance - TradingView
AbbVie: Upside Potential And Dividends With Competent Portfolio Renewal (NYSE:ABBV) - Seeking Alpha
ABBV: Cantor Fitzgerald Lowers Price Target, Maintains Overweigh - GuruFocus
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Cantor Fitzgerald lowers Abbvie stock price target on valuation - Investing.com
BOTOX® Cosmetic (onabotulinumtoxinA) Empowers Women Entrepreneurs Through "The Confidence Collective" for Fourth Year - AbbVie News Center
$20,000 grants return as BOTOX reopens program for 250 women - Stock Titan
AbbVie Stock Review 2026: Earnings Outlook, Dividend Yield, and ValuationNews and Statistics - IndexBox
Ethos Capital Buys Stake in AbbVie - National Today
Can AbbVie’s (ABBV) New Dermatology Data Quietly Reshape Its Immunology-Heavy Investment Story? - Yahoo Finance
AbbVie: Lowered Guidance Is Just NoiseReiterate Buy - Seeking Alpha
AbbVie Continues to Raise Quarterly Dividend Amid Patent Challenges - Intellectia AI
This Pharma Dividend Has Been Raised Every Single Year for Over a Decade - Yahoo Finance
Allergan Aesthetics Third State-of-the-Art AMI Center Opens in Austin - Investing News Network
AbbVie Gets JPMorgan Buying Opportunity Call With $260 Price Target Amid Competitive Concerns - AOL.com
0.47%
자본화:
|
볼륨(24시간):